Trispecific Antibodies To Drive Designer Antibody Market Says Kuick Research
Report Gives Comprehensive Insight On All Parameters Associated With The Development Of global Trispecific market Landscape
NEW DELHI, Feb. 15, 2021 /PRNewswire/ -- "Global Trispecific Antibodies Market Opportunity & Clinical Trials Insight 2024" Report Highlights:
- Commutative Market Opportunity During Initial 5 years of Commercialization: > US$ 2 Billion
- Trispecific Antibodies In Clinical Trials: > 8 Antibodies
- Highest Phase of Development: Phase I/II
- Cancer Dominating Trispecific Antibodies Trials: > 5 Antibodies
- Numab Therapeutics Dominating the Trispecific Development Pipeline
- Prevention & Second Line Therapy Key Focus of Development of Trispecific Antibodies
Report Table of Content
1. Introduction to Global Trispecific Cancer Antibody Drug Market
1.1 Trispecific Cancer Antibody Mechanism of Action Against Cancer Cells
1.2 History of the Development of Trispecific Cancer Antibody Drug Development
2. Cancer Cases Engaging More Potential Trispecific Cancer Research Studies at Clinical Level
2.1 Trispecific Cancer Antibody Drug Therapy Market Beneficial for all Cancer Types
2.2 Potential Trispecific Cancer Antibody Therapy for Non-Small Cell Lung Cancer
2.3 Potential Trispecific Cancer Antibody Drug Therapy for the Treatment of Breast
Cancer
2.4 Potential Trispecific Cancer Antibody Therapy Market for Prostate Cancer
2.5 Potential Trispecific Cancer Antibody Therapy Market for Rest of the Cancer
Types
2.6 Trispecific Cancer Antibody Drug Immunotherapy Market as a Saviour for
Increasing Prevalence of Cancer Cases
2.7 Trispecific Antibody Immunotherapy Market Clinical Experience
3. Clinical Insights for Current Trispecific Cancer Antibody Drug Therapy Market
3.1 Importance of Clinical Research Studies for the Overall Development of
Trispecific Cancer Antibody Drug Therapy Market
3.2 Research Clinical Insights for Trispecific Cancer Antibody Drug Therapy against
Multiple Myeloma
4. Trispecific Cancer Antibody Drug Therapy Market Overcoming the Challenges for Monoclonal Antibody & Bispecific Antibody Drug Market
4.1 Trispecific Cancer Antibody Drug Therapy Market an Enhanced Version of
Monoclonal Antibody Therapy Market
4.1.1 Trispecific Cancer Antibody Drug Therapy Vs. General Monoclonal Antibody
Drug Class
4.1.2 Construction Benefits of Using Trispecific Cancer Antibody Drug Therapy Over
Monoclonal Antibodies
4.2 Trispecific Cancer Antibody Drug Therapy in Overcoming Bispecific Cancer
Antibody Drug Therapy Challenges
5. Tri-Specific Natural Killer Cell Nanoengagers to Address Cancer Therapeutic Indication
6. Forging Novel Pathways for Improving Research & Development Sector for Cancer by Trispecific Cancer Antibody Therapy
6.1 Trispecific Cancer Antibody Drug Therapy Market Research & Development Sector
Promoting Current Cancer Therapy Market
6.2 Novel Trispecific Cancer Antibody Therapy Drugs to Boost Chemotherapy Cancer
Market
6.3 Novel Trispecific Cancer Antibody Drug Market Boosting the Future Radiation
Therapy Market
6.4 Novel Trispecific Cancer Antibody Drug Market Boosting Other Available Cancer
Therapies Market
7. Global Market Implications for Ongoing Research Studies & Collaborations for Trispecific Cancer Antibody Drug Market
7.1 Numab & Vasella Therapeutics to Collaborate for PD-L1x4-1BBxHSA Trispecific
ND021 Candidate in the Cancer Patients
7.2 GTB-3550 Trispecific Recombinant Fusion Protein Development by GT Biopharma
7.3 Sanofi to Target Bi-specifcic & Multi-Specific Antibodies for Overall Development
of Cancer Pharmaceutical Industry
7.4 Sunshine Pharmaceuticals & Numab Therapeutics to Undergo Partnership for the
Development of Multi-Specific Cancer Antibody Drugs for Cancer Patients
7.5 SAR 441236 Trispecific Cancer Antibody Drug Development by Brigham Health
Hospital
7.6 Numab Therapeutics Evaluation of NM21-1480 Trispecific Cancer Antibody in the
Solid Cancer Patients
8. Global Trispecific Antibodies Clinical Pipeline Overview
8.1 By Country
8.2 By Indication
8.3 By Organization
8.4 By Patient Segment
9. Global Trispecific Antibodies Pipeline Clinical Insight By Company, Indication & Phase
9.1 Reserach
9.2 Preclinical
9.3 Phase-I
9.4 Phase-I/II
10. Insight for Driving Factors & Challenges for the Trispecific Cancer Antibody Drug Market
10.1 Driving Parameters for Trispecific Cancer Antibody Drug Market
10.2 Challenge Observed for the Current Trispecific Cancer Antibody Drug Therapy
Market
11. Future Directions for Trispecific Cancer Antibody Drug Therapy Market at Global Level
12. Competitive Landscape
12.1 AbbVie
12.2 Affimed
12.3 Biotheus
12.4 Harpoon Therapeutics
12.5 Macrogenics
12.6 Numab
12.7 Sanofi
12.8 Sichuan Baili Pharmaceuticals
The pace at which a respective cancer patient gets treated is accelerating. For the past four to five decades, a cluster of innovative treatments often applied alone or in combination with other viable therapies have been frequently increasing the survival rate of the cancer patients. Cancer trispecific antibodies for the cancer patients is one of the emerging areas of therapeutic sector arrived from splendid research and development pipeline. As the number of cancer case landscape is shifting rapidly, therefore bringing novel treatment such as trispecific antibodies to the patients has provided appropriate care to the cancer patients while ensuring the sustainability of the treatment.
Trispecific antibodies enhance the efficacy of the treatment by targeting T- cells and tumor cells. Efficient targeting, minimal side effects and increased effectiveness of the cancer treatment and many other are contributing to the increased level of spending on the research and development concerned with trispecific antibodies. It has been estimated that the total global spending on the development of the treatment reached gazillion dollars. The growing concern of the increasing burden of cancer cases got reflected, which in-turn tuned the researchers to develop a treatment that is more specific i.e. with no off-target activity.
The existing mechanism of action of the trispecific antibodies in almost all the solid cancer patients are incrementally improving the patient outcomes, which is reflected in the increasing five-year survival rates of the stage IV cancer patients. The market of the therapeutic regimen is associated with a healthy pipeline of novel drugs and combinations, estimated to bring rapid and significant healthcare benefits. The current landscape of the therapy as a strong immunologic action address multiple targets, leading to potentially a substantial market growth. The coupling of the market with strong pipeline in the clinical development also suggests the strong and direct competition between the cancer treatments. It is believed that the therapy inside the body generates a battleground in which maximum times, cancer cells gets defeated.
As per the report findings for Cancer trispecific antibodies, the spiraling research and development associated with the cancer trispecific agents and the shorter product efficacy of other treatment regimen have fragmented the cancer market more towards antibodies targeting three different molecules. The potential return from the respective treatment and the wide-range of positive outcomes received from the treatment is estimated to develop a higher demonstrative value among all the cancer researchers, patients and clinicians. The novel entrant in the cancer therapeutics markets is believed to evolve in line and provide tremendous opportunities for the patients who are in danger of getting no-treatment response from other commercially available treatments. The arrival of cancer trispecific antibodies is estimated to change the overall oncology paradigm and highest returns to the patients investing in the treatment.
Contact:
Neeraj Chawla
neeraj@kuickresearch.com
+91-981041036
Logo: https://mma.prnewswire.com/media/1245952/Kuick_Research_Logo.jpg
Share this article